Reducing Disparities in Medication Adherence in SLE

Not Applicable

Completed

• Conditions: Systemic Lupus Erythematosus

• Registration Number: NCT03738826
• Lead Sponsor: Duke University

Brief Summary

This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-11-06
• Study First Submitted QC: 2018-11-08
• Study First Posted: 2018-11-13
• Study Start: 2019-10-02
• Primary Completion: 2020-06-07
• Study Completion: 2020-06-07
• Results First Submitted: 2021-05-27
• Results First Submitted QC: 2021-07-08
• Results First Posted: 2021-07-27
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-13
• Last Update Posted: 2025-06-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 135

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Acceptability as Measured by Provider Survey	12 weeks	Acceptability as measured by provider survey, score range 1-5, with a higher score indicating that the intervention was more acceptable.
Feasibility as Measured by Number of Participants With EMR (Electronic Medical Record) Documentation of Adherence	12 weeks	Feasibility as measured by documentation of adherence assessment made by provider.

Secondary Outcome Measures

Name	Time	Method
Percentage of Adherent Participants as Determined by Medication Possession Ratio (MPR)	Baseline, 12 weeks	Medication Possession Ratio (MPR) = days with medication/total days. This will be determined by pharmacy refill data and calculated for 3 months (90 days). An MPR \> or = 80% indicates adherence.
Medication Adherence as Determined by Self Report	12 weeks

Trial Locations

Locations (1)

Duke University; 🇺🇸 Durham, North Carolina, United States